A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
← catalyst calendarSponsored by Toray Industries, Inc (industry) · 3402.T — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
146estimated
Sites
27
Countries
Japan, South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-04 | actual | When the study began enrolling |
| Primary completion | 2026-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Adenocarcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Interventions
- Biological: TRK-950
- Drug: Ramucirumab — also filed as CYRAMZA®
- Drug: Paclitaxel
Primary outcome
what the primary-completion date above is the date OFProgression free Survival (PFS)
measured Time from date of randomization to the date of progressive disease or death due to any cause, whichever occurs first, up to approximately 24 months
Publications
- PMID 41979863 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 3402.T's whole pipeline · Catalyst calendar · Every registered study · What changed